The Tisch Cancer Institute

Center for Novel Therapeutics

Key to advancing optimal cancer care—the overarching mission of The Tisch Cancer Institute (TCI)—is the pursuit of novel therapies based on scientific investigation that lead to the most effective care for the best outcomes with minimal adverse events.

The Novel Therapeutics/Phase I Program at TCI, a crucial component for advancing cancer treatment under the leadership of medical director Matthew Galsky, MD, Professor of Medicine facilitates early phase clinical trials to maximize the development of cutting-edge therapies. With an emphasis on first-in-human and biomarker focused proof-of-concept studies, the program promotes the translation of scientific discoveries from TCI laboratories to the clinic setting, such that the latest drugs and technologies that may favorably impact patient outcomes can be offered. Sometimes new drugs are piloted. Other times drugs may be combined in novel fashions, or administered in ways that are hypothesized to be more effective, such as injection directly into tumors.

The program is important as a vehicle for moving the explosion of cancer immunotherapy research to clinical applications. It also serves as a hub for precision medicine cancer trials by fostering seamless integration of oncology, genomics, computational biology, pathology, interventional radiology, and diagnostic radiology.

Meet Our Team

Matthew Galsky, MD
Medical Director
Matthew.galsky@mssm.edu

Lynn Bui, MS
Project Manager
Lynn.bui@mssm.edu

Thomas Marron, MD
Immunotherapy
Thomas.marron@mssm.edu

Nina Bhardwaj, MD
Immunotherapy
Nina.bhardwaj@mssm.edu

Joshua Brody, MD
Immunotherapy
Joshua.brody@mssm.edu